Table of contents

• Stem Cell Disease Therapy at a Glance
• What Is Stem Cell Disease Therapy?
• Who Is a Good Candidate for Stem Cell Disease Therapy?
• How Is Stem Cell Disease Therapy Performed?
• Why Visit Korea for Stem Cell Disease Therapy?
• Key Information for International Patients
• Which Are the Best Clinics in Korea for Stem Cell Disease Therapy?
• Stem Cell Disease Therapy From Start to Finish
• Alternatives to Stem Cell Disease Therapy
• How Can I Prepare for Stem Cell Disease Therapy?
• Aftercare Advice

Considering treatment in Korea? Everything you need to know e.g. — how to avoid scams, visas, interpreters, recovery tips — in our Medical Tourism Master Guide. Plan with confidence in minutes, not weeks!

Last updated: September 2026

Stem Cell Disease Therapy at a Glance

• Not one standard treatment — “Stem cell disease therapy” can mean established hematopoietic stem-cell transplantation (HSCT), a defined cell product, or an investigational trial; the cell source, dose, route, disease indication, and evidence must be confirmed for the exact treatment.
• Established use is selective — HSCT is specialist treatment for selected blood cancers, bone-marrow failure disorders, and inherited blood or immune conditions—not a general therapy for fatigue, aging, chronic pain, neurological disease, or cancer without a disease-specific indication.
• Two main transplant approaches — Autologous HSCT uses the patient’s own collected blood-forming cells after high-dose treatment and avoids donor GVHD; allogeneic HSCT uses donor cells, which may add an anti-disease immune effect but can cause graft-versus-host disease and graft failure.
• Long Korea stay for HSCT — An uncomplicated autologous transplant commonly requires several weeks near the transplant center, while allogeneic transplant generally requires about 100 days of close local follow-up before return travel may be considered.
• Recovery takes months to years — Conditioning commonly lasts 1–2 weeks, and cells are infused by IV on day zero; immune recovery generally takes several months after autologous HSCT and about 1–2 years after allogeneic HSCT.
• Korea requires pathway verification — Korea’s advanced-regenerative-medicine framework does not authorize every cell treatment for every disease; obtain written proof of the product identity, regulatory pathway, hospital availability, international-patient eligibility, risks, and follow-up plan.
• No generic cost or repeat-session plan — No reliable general price, maintenance schedule, or repeat-dose plan applies because costs and repeat treatment depend on the diagnosis, transplant type or named product, admission needs, donor planning, and formal protocol.

What Is Stem Cell Disease Therapy?

Stem cell disease therapy is an umbrella term for treatments that use blood-forming stem cell transplantation or a defined cell product for a specific disease. It aims to restore blood or immune function, control certain cancers or inherited disorders, or test a targeted therapy when standard care is insufficient. It can be surgical, minimally invasive, or non-surgical, depending on the exact treatment.

Who Is a Good Candidate for Stem Cell Disease Therapy?

• Established HSCT candidates — People with selected blood cancers, bone-marrow failure disorders, or inherited blood or immune conditions whose hematologist considers hematopoietic stem-cell transplantation (HSCT) appropriate.
• Autologous-transplant candidates — People whose own blood-forming stem cells can be collected and reinfused after high-dose treatment; this approach does not carry donor graft-versus-host disease (GVHD).
• Allogeneic-transplant candidates — People with a disease for which donor cells offer a justified benefit and who have a feasible donor strategy, sufficient organ function, and capacity for prolonged monitoring.
• Product- or trial-specific candidates — People who meet the written eligibility criteria for an exact disease-specific cell product or formally reviewed clinical study.

This is not a general treatment for chronic pain, fatigue, aging, cancer, or neurological disease simply because cells are described as “stem cells.” Stem-cell treatments must be assessed by disease and cell type, not marketed as one intervention for unrelated conditions. For HSCT, uncontrolled infection, serious uncontrolled heart, lung, liver, or kidney disease, poor functional reserve, or inability to maintain intensive follow-up can require delay or rule out transplant. Allogeneic HSCT also requires careful assessment of donor availability, graft failure, transplant-related mortality, and GVHD. Pregnancy, breastfeeding, fever, anticoagulants, antiplatelet drugs, immunosuppressants, chemotherapy, and investigational medicines require specialist review; the transplant or disease team makes the final decision after reviewing disease risk, prior treatment, organ function, and practical support.

How Is Stem Cell Disease Therapy Performed?

“Stem cell disease therapy” covers fundamentally different interventions. Confirm the exact cell source, product name, manufacturer, dose, route, disease indication, and regulatory basis before considering travel.

• Autologous HSCT — The team mobilizes and collects the patient’s own blood-forming stem cells, preserves them, gives conditioning treatment, then reinfuses the cells. It avoids donor GVHD but does not provide a donor immune anti-disease effect.
• Allogeneic HSCT — Blood-forming cells come from a related, unrelated, haploidentical, or cord-blood donor under a disease-specific plan. Donor immune cells can help fight disease but can also attack the recipient’s tissues, causing GVHD, graft failure, and prolonged immunosuppression. NCI explains these transplant distinctions and risks.
• Condition-specific cellular product — A defined product can be autologous or donor-derived and delivered intravenously, locally, intrathecally, intra-arterially, or during surgery. Different cell sources and administration routes are not interchangeable, and a short injection is not automatically low risk.
• Clinical-trial cell therapy — Investigational treatment requires a written protocol, ethics review, disease-specific eligibility criteria, informed consent, adverse-event reporting, and a defined follow-up plan. A trial listing does not establish effectiveness, authorization, or adequate oversight.

Why Visit Korea for Stem Cell Disease Therapy?

South Korea has an advanced-regenerative-medicine framework, but that framework is not blanket permission to use any cell product for any disease. The critical issue is whether a specific hospital can document an appropriate, currently available pathway for the exact diagnosis. Do not treat a clinic webpage, patient testimonial, or general claim of Korean regulation as proof of efficacy or access.

• Regulatory oversight functions — Korea’s advanced-regenerative-medicine framework covers cell therapy, gene therapy, tissue engineering, and fusion therapy, with designated institutions and review of clinical research plans. MFDS also evaluates quality, safety, and efficacy of relevant cell and gene therapy products.
• Need for verifiable documentation — Ask whether care is an MFDS-authorized marketed product, an approved advanced-regenerative-medicine treatment-pathway intervention, or regulated clinical research. Authorization status, labeling, hospital supply, protocol enrollment, and international-patient eligibility can change independently.
• Specialist transplant care — For eligible hematologic conditions, HSCT requires a transplant program able to coordinate conditioning, cell infusion, transfusion support, infection prevention, laboratory surveillance, and management of organ complications. HSCT is established specialist care, not a generic regenerative infusion.

Key Information for International Patients

• Minimum stay — Do not plan this as a one-visit medical-tourism treatment. An uncomplicated autologous transplant commonly requires several weeks near the transplant center; allogeneic transplantation generally requires about 100 days of close local follow-up before return home can be considered.
• Flight timing — There is no universal “safe to fly” date. The transplant team must assess blood counts, infection and clotting risk, oxygenation, transfusion needs, central-line status, medication access, and emergency arrangements before clearing air travel.
• Local accommodation and caregiver — Arrange housing near the hospital and a reliable caregiver when required by the transplant program. One major center advises remaining within about one hour of the treating center during the first three months after autologous transplant and discussing air travel with the transplant team first. See its post-transplant travel guidance.
• Repeat visits and recovery — HSCT recovery takes months, not days. Immune recovery generally takes several months after autologous HSCT and about one to two years after allogeneic HSCT; repeat transplant or repeat dosing depends on diagnosis and formal protocol, not a maintenance schedule.
• Remote follow-up — Before leaving Korea, secure a named clinician at home and obtain an English discharge summary, procedure note, product and batch details where applicable, cell source, dose, route, laboratory results, medication list using generic names, and emergency contacts.

Travel note: A defined non-HSCT cell product or clinical study can have a shorter treatment visit, but the stay cannot be estimated safely without its exact protocol, adverse-event plan, dosing schedule, and Korean and home-country follow-up arrangements.

Which Are the Best Clinics in Korea for Stem Cell Disease Therapy?

Listed below are some of the best clinics in Korea for stem cell disease therapy.

1. Cellinique Clinic

At Cellinique Clinic, you can expect a personalized regenerative-care consultation centered on stem cell technology, including its NovaStem approach using concentrated autologous blood. The clinic’s documented focus is on immunity, regeneration, overall health, and aesthetic applications, so whether its services fit your specific disease-related needs should be determined through an individual medical assessment rather than assumed from its broader wellness offerings.

• URL: Cellinique Clinic Website
• Location: Gangnam-gu, Seoul
• Regenerative approaches:
  • NovaStem uses concentrated autologous blood with the stated aim of activating aged cells and supporting damaged-tissue regeneration.
  • The clinic also lists stem cell therapy for tissue repair, metabolic-function support, and overall health management.
  • Complementary options listed include PRP, NK cell therapy, exosomes, stem cell fat grafting, and blood purification.
• Clinical focus:
  • Cellinique operates as a one-doctor clinic with care described as fully personalized.
  • Dr. Chris Gunwoo Kim has presented on blood stem cells, tissue regeneration, SDF-1alpha injection, and the clinic’s NovaStem Kit at professional meetings.

2. SH Clinic

You may consider SH Clinic if you want an in-person, personalized stem cell treatment assessment for conditions the clinic lists across neurology, immunology, musculoskeletal care, and health management. Its stated disease-related offerings include autoimmune disease, arthritis and disc disease, cerebral infarction, and dementia, with treatment planning performed by experienced medical staff after consultation and examination.

• URL: SH Clinic Website
• Location: Seocho-gu, Seoul
• Conditions and programs listed:
  • SH Clinic lists stem cell treatment programs for autoimmune disease, cerebral infarction, dementia, arthritis, and disc disease.
  • Its Wellness & Anti-aging Program is described as drawing on clinical experience to tailor stem cell treatments.
  • Additional listed applications include hair loss, skin rejuvenation, female health, and male sexual function.
• Treatment planning:
  • The clinic states that care is personalized after an in-person consultation and examination.
  • A BMAC stem cell knee injection is listed for arthritic knees, using concentrated bone-marrow cells.

3. Lydian Plastic Surgery Clinic

At Lydian Plastic Surgery Clinic, you can ask about stem cell therapy within an advanced regenerative-medicine system that can extract, test, and process human cells from bone marrow, fat, or blood. The clinic emphasizes controlled cell-processing and clean-room standards; however, its supplied information does not specify disease-focused treatment programs, so your eligibility and the intended use of any therapy require a clinician’s individualized evaluation.

• URL: Lydian Plastic Surgery Clinic Website
• Location: Gangnam-gu, Seoul
• Regenerative medicine system:
  • Lydian is described as an Advanced Regenerative Medicine Provider approved by the Ministry of Health and Welfare.
  • Its system includes authorized Cell Processing Facilities for cell extraction, testing, and processing.
  • The clinic lists bone marrow, fat, and blood as potential stem cell sources, with extraction customized to individual needs.
• Processing environment:
  • The facility states that it maintains Clean Class 10,000 standards.
  • Disposable stem cell extraction kits are used as part of the clinic’s infection-risk-minimization measures.
  • Its regenerative system is described as including verified cell management, extraction processes, and equipment calibration.
• Related regenerative service:
  • Stem cell fat grafting is listed as a procedure that harvests fat, enriches it with stem cells, and reinjects it for volume enhancement in areas such as the face, breasts, or buttocks.
  • The clinic describes stem cell therapy in regenerative and cosmetic contexts, including support for healing and tissue regeneration.

Stem Cell Disease Therapy From Start to Finish

1. Remote specialist review — Submit complete records for an English-language or virtual consultation where available: diagnosis, pathology and molecular reports, imaging, blood counts, prior-treatment history, medicines, allergies, infection history, and a referral from the home specialist. Do not stop established disease treatment to travel for an unproven intervention.
2. Confirm the proposed pathway — Obtain written confirmation of the disease indication, cell source, processing method, product or manufacturer identity, dose, route, expected benefit, known risks, regulatory basis, costs, admission plan, emergency coverage, and follow-up schedule.
3. In-person evaluation — For HSCT, the transplant team assesses transplant indication, cardiac, pulmonary, liver, kidney, dental, nutritional, infectious-disease, and venous-access status. Allogeneic treatment also requires HLA typing and donor planning.
4. Collection and conditioning for autologous HSCT — The team mobilizes and collects blood-forming stem cells, then gives high-dose chemotherapy and sometimes radiation. Conditioning commonly lasts one to two weeks.
5. Cell administration — On “day zero,” HSCT cells are infused through an IV catheter. A non-HSCT product follows its specific protocol; collection, manufacturing wait time, anesthesia or sedation, route, and admission status cannot be generalized.
6. Observation and early recovery — HSCT patients receive frequent blood-count checks, transfusion support when needed, infection prevention, symptom management, and monitoring for engraftment and organ complications. For an allogeneic transplant, the team also monitors for GVHD.
7. Discharge planning in Korea — Leave hospital only when the treating team considers outpatient monitoring appropriate. Receive written medication, food-safety, infection-prevention, line-care, activity, and emergency instructions in a form the home clinician can use.
8. Overseas follow-up — Continue the transplant or product-specific surveillance plan with the Korean team and named home clinician. Send scheduled laboratory results and seek urgent local assessment for concerning symptoms rather than waiting for a remote reply.

Alternatives to Stem Cell Disease Therapy

The appropriate alternative depends on the diagnosis, disease stage, prior treatment, and whether the proposed cell intervention is established care or investigational. For a condition with an established transplant indication, the decision is usually between transplant strategies and disease-directed therapy; for a proposed non-HSCT cell product, compare it with guideline-supported treatment rather than with vague promises of regeneration.

Disease-Directed Medical Therapy

• Examples — Chemotherapy, targeted therapy, immunotherapy, radiotherapy, biologic medicines, transfusions, or disease-modifying medicines can be standard care for the underlying condition.
• Tradeoff — These options have disease-specific evidence and established monitoring pathways, while many non-HSCT cell interventions remain investigational.

Supportive or Palliative Care

• Role — Symptom control, infection treatment, rehabilitation, nutritional support, transfusion support, and palliative care can improve function and quality of life alongside, or instead of, intensive disease treatment.
• Tradeoff — Supportive care does not replace potentially curative treatment where that is appropriate, but it avoids the conditioning and immune risks of transplant when intensive treatment is unsuitable.

Alternative Transplant Strategy

• Options — Depending on the hematologic disease, specialists can consider autologous versus allogeneic transplantation, different donor approaches, or deferring transplant while other treatment is used.
• Tradeoff — An allogeneic transplant can offer a donor immune effect but adds GVHD, graft-failure, and prolonged immunosuppression risks. For a separate discussion of an autologous approach, see autologous stem cell therapy.

Non-Cell Clinical Trial

• Role — A disease-specific trial of a drug, biologic, device, surgery, or combination treatment can be a more appropriate research option than an unspecified cell infusion.
• Tradeoff — Trial participation has uncertainty and eligibility limits, but legitimate trials define the intervention, safety monitoring, adverse-event reporting, and follow-up.

How Can I Prepare for Stem Cell Disease Therapy?

• Send complete records early — Provide the home specialist’s referral, diagnosis and staging records, pathology and genetic reports, imaging, laboratory trends, treatment history, vaccination and infection history, and a current medication and allergy list.
• Disclose every medicine and supplement — List prescription drugs, over-the-counter medicines, anticoagulants, antiplatelet drugs, steroids, diabetes medicines, antiseizure medicines, immunosuppressants, cancer drugs, vitamins, herbal or traditional products, fish oil, and recreational substances. Do not independently stop any of them.
• Follow fasting instructions exactly — Cell infusion alone does not necessarily require fasting. Bone-marrow harvest, central-line placement, surgery, anesthesia, or sedation can require fasting; use only the treating team’s written schedule.
• Resolve active health issues — Report fever, cough, diarrhea, dental infection, skin wounds, recent hospitalization, new medicines, and exposure to contagious illness before travel. HSCT eligibility and timing depend strongly on infection control and organ function.
• Plan protected accommodation — Arrange housing near the transplant center, a caregiver if required, local transport, and flexible flights. Do not book a return flight based on a fixed calendar date before the team has reviewed recovery.
• Prepare continuity of care — Identify a hematologist, oncologist, or other disease specialist at home before departure and confirm who can order laboratories, prescribe medicines, and arrange emergency care after return.

Travel note: Request written confirmation of the exact treatment pathway and anticipated stay before paying deposits or changing long-term disease treatment.

Confirm clinic-specific testing, medication, fasting, caregiver, accommodation, and travel requirements with the treating doctor; individualized instructions take precedence over general guidance.

Aftercare Advice

After HSCT or any disease-specific cell intervention, treat new symptoms seriously and follow the written protocol rather than relying on a generic recovery schedule.

• Monitoring and medicines — Attend all blood tests, transplant reviews, and product-specific safety assessments. Take prescribed antimicrobial, anti-nausea, immunosuppressive, pain, or other medicines exactly as directed; do not add supplements or stop medicines without approval.
• Infection protection — Avoid people who are ill and follow the team’s restrictions on crowds, food and water safety, dental work, swimming, work, and travel. Immune recovery takes months after autologous HSCT and roughly one to two years after allogeneic HSCT.
• Activity and line care — Increase activity only as the team permits, protect central lines from contamination, and follow specific instructions for bathing, dressing changes, lifting, and exercise. Fatigue and loss of conditioning are common after transplant.
• Urgent warning signs — Seek immediate medical assessment for fever or chills, breathing difficulty, chest pain, fainting, confusion, bleeding, uncontrolled vomiting or diarrhea, reduced urine, severe headache, catheter redness or drainage, one-sided limb swelling, jaundice, or sudden deterioration.
• GVHD symptoms after donor transplant — Report a new or worsening rash, diarrhea, abdominal pain, jaundice, dry eyes or mouth, breathing symptoms, or genital symptoms promptly. GVHD can occur after allogeneic HSCT and needs specialist assessment.
• Result timeline — Engraftment and improved blood counts are early milestones, not proof of final disease control. Functional recovery is variable; about three months is common after autologous transplant, though recovery can take longer. Post-transplant recovery guidance emphasizes this variability.

Follow the treating doctor’s instructions and contact the Korean team and local clinician promptly when anything appears wrong.